title: Clinical effects of recombinant human interleukin-3.
abstract: Interleukin-3 (IL-3) is a glycoprotein belonging to the hematopoietic growth factor family that in preclinical in vitro and in vivo studies has exhibited a multilineage activity. Phase I/II trials with recombinant human IL-3 (rhIL-3) expressed in yeast are being done in patients with advanced malignancies as well as in patients with bone marrow failure states. Subcutaneous administration of rhIL-3 at dosages between 30 and 500 micrograms/m2 for 15 consecutive days has resulted in a dose-dependent increase in platelet counts as well as in a substantial increase in the number of circulating neutrophils, eosinophils, monocytes, and lymphocytes in patients with advanced malignancies but normal hematopoiesis. Erythropoiesis is less stimulated with an increase in hemoglobin concentration only in a minority of patients. In patients with secondary hematopoietic failure due to prolonged chemo-/radiotherapy or bone marrow infiltration by tumor cells, treatment with rhIL-3 leads to a clinically significant restoration of hematopoiesis, especially of thrombopoiesis and granulopoiesis. rhIL-3 has also been shown to improve neutrophil and platelet counts in patients with myelodysplastic syndromes, while improvement of hematopoiesis is rarely observed in patients with severe aplastic anemia with the presently used treatment schedules. Adverse effects of rhIL-3 are minor at the clinically used dosages and include fever, bone pain, headache, and stiffness of the neck. Transient thrombocytopenia has been observed in a few patients with myelodysplastic syndrome or aplastic anemia treated at dosages of 250-500 micrograms/m2. rhIL-3 is a multilineage hematopoietic cytokine with promising effects on platelet and neutrophil counts and special usefulness in patients with secondary hematopoietic failure.
authors.affiliation: Department of Hematology, University of Frankfurt, F.R.G.
authors.forename: A
authors.initials: A
authors.lastname: Ganser
authors.forename: A
authors.initials: A
authors.lastname: Lindemann
authors.forename: G
authors.initials: G
authors.lastname: Seipelt
authors.forename: O G
authors.initials: OG
authors.lastname: Ottmann
authors.forename: F
authors.initials: F
authors.lastname: Herrmann
authors.forename: M
authors.initials: M
authors.lastname: Eder
authors.forename: J
authors.initials: J
authors.lastname: Frisch
authors.forename: G
authors.initials: G
authors.lastname: Schulz
authors.forename: R
authors.initials: R
authors.lastname: Mertelsmann
authors.forename: D
authors.initials: D
authors.lastname: Hoelzer
mesh_terms: D000741:Anemia, Aplastic / Q000628:therapy; D000818:Animals; D001772:Blood Cell Count / Q000187:drug effects; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D007377:Interleukin-3 / Q000493:pharmacokinetics / Q000627:therapeutic use*; D009190:Myelodysplastic Syndromes / Q000628:therapy; D009369:Neoplasms / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D007377:Interleukin-3; D011994:Recombinant Proteins